Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating
tablets of Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, Inc. USA) with
Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc.,
USA in healthy, adult, human male subjects under fed condition.